(no author information available yet)
Tang, Y. H., He, G. L., Huang, S. Z., Zhong, K. B., Liao, H., Cai, L., Gao, Y., Peng, Z. W., & Fu, S. J. (2019), The long noncoding RNA AK002107 negatively modulates miR-140-5p and targets TGFBR1 to induce epithelial-mesenchymal transition in hepatocellular carcinoma. Mol Oncol, 13(5): 1296-1310. The above article, published online on 11 April 2019 in Wiley Online Library (, has been retracted by agreement between the journal Editor-in-Chief, Kevin Ryan, FEBS Press, and John Wiley and Sons Ltd...
June 14, 2024: Molecular Oncology
Eric Eldering, Jean-Ehrland Ricci
The field of immunometabolism cannot be considered 'emerging' anymore; it is at the moment one of the most active and rapidly evolving areas of biomedical research. Its hottest zone is cancer immunometabolism. This is partly due to the clinical application of immunotherapy, with either antibodies (checkpoint blockade) or cellular therapies (e.g., CAR-T cells). In addition, the proliferating tumor cells create a nutrient-deprived microenvironment that impairs the metabolic fitness and functionality of infiltrating immune cells such as T cells, NK cells, and macrophages...
June 13, 2024: Molecular Oncology
Eva Valentina Klocker, Samantha Hasenleithner, Rupert Bartsch, Simon P Gampenrieder, Daniel Egle, Christian F Singer, Gabriel Rinnerthaler, Michael Hubalek, Katja Schmitz, Zsuzsanna Bago-Horvath, Andreas Petzer, Sonja Heibl, Ellen Heitzer, Marija Balic, Michael Gnant
The advancements in the detection and characterization of circulating tumor DNA (ctDNA) have revolutionized precision medicine and are likely to transform standard clinical practice. The non-invasive nature of this approach allows for molecular profiling of the entire tumor entity, while also enabling real-time monitoring of the effectiveness of cancer therapies as well as the identification of resistance mechanisms to guide targeted therapy. Although the field of ctDNA studies offers a wide range of applications, including in early disease, in this review we mainly focus on the role of ctDNA in the dynamic molecular characterization of unresectable locally advanced and metastatic BC (mBC)...
June 12, 2024: Molecular Oncology
(no author information available yet)
M. Lagadari, N. R. Zgajnar, L. I. Gallo and M. D. Galigniana, 'Hsp90-binding immunophilin FKBP51 forms complexes with hTERT enhancing telomerase activity', Molecular Oncology 10, no. 7 (2016): 1086-1098, The above article, published online on 17 May 2016 in Wiley Online Library (, has been retracted by agreement between the journal Editor in Chief, Kevin Ryan and John Wiley and Sons Ltd. The retraction has been agreed due to several instances of image manipulation in figures 1C, 5B, 4A and 5A...
June 5, 2024: Molecular Oncology
(no author information available yet)
L. Wang, Y. Gao, D. Tong, X. Wang, C. Guo, B. Guo, Y. Yang, L. Zhao, J. Zhang, J. Yang, Y. Qin, L. Liu, and C. Huang, "MeCP2 Drives Hepatocellular Carcinoma Progression Via Enforcing HOXD3 Promoter Methylation and Expression Through the HB-EGF/EGFR Pathway," Molecular Oncology 15, no. 11 (2021): 3147-3163, The above article, published online on 24 May 2021 in Wiley Online Library (, has been retracted by agreement between the journal Editor-in-Chief, Kevin Ryan; FEBS Press; and John Wiley and Sons Ltd...
June 5, 2024: Molecular Oncology
Maite G Fernández-Barrena, Matías A Avila
Rewiring of cellular metabolism is now fully recognized as a hallmark of cancer. Tumor cells reprogram metabolic pathways to meet the energetic and macromolecular demands to support unrestricted growth and survival under unfavorable conditions. It is becoming apparent that these adaptations underpin most of the traits that define a cancer cell's identity, including the ability to avoid immune surveillance, endure nutrient and oxygen restrictions, detach and migrate from their natural histological niche, and avert human-made aggressions (i...
June 4, 2024: Molecular Oncology
(no author information available yet)
No abstract text is available yet for this article.
May 29, 2024: Molecular Oncology
Jonas Wohlfarth, Corinna Kosnopfel, Dominic Faber, Marion Berthold, Claudia Siedel, Melissa Bernhardt, Andreas Schlosser, Tyler Aprati, David Liu, David Schrama, Roland Houben, Dirk Schadendorf, Matthias Goebeler, Svenja Meierjohann, Bastian Schilling
Immunotherapy has achieved tremendous success in melanoma. However, only around 50% of advanced melanoma patients benefit from immunotherapy. Cyclin-dependent kinase inhibitor 2A (CDKN2A), encoding the two tumor-suppressor proteins p14ARF and p16INK4a , belongs to the most frequently inactivated gene loci in melanoma and leads to decreased T cell infiltration. While the role of p16INK4a has been extensively investigated, knowledge about p14ARF in melanoma is scarce. In this study, we elucidate the impact of reduced p14ARF expression on melanoma immunogenicity...
May 28, 2024: Molecular Oncology
Anne Clavreul, Catherine Guette, Hamza Lasla, Audrey Rousseau, Odile Blanchet, Cécile Henry, Alice Boissard, Mathilde Cherel, Pascal Jézéquel, François Guillonneau, Philippe Menei, Jean-Michel Lemée
Proteomics has been little used for the identification of novel prognostic and/or therapeutic markers in isocitrate dehydrogenase (IDH)-wildtype glioblastoma (GB). In this study, we analyzed 50 tumor and 30 serum samples from short- and long-term survivors of IDH-wildtype GB (STS and LTS, respectively) by data-independent acquisition mass spectrometry (DIA-MS)-based proteomics, with the aim of identifying such markers. DIA-MS identified 5422 and 826 normalized proteins in tumor and serum samples, respectively, with only three tumor proteins and 26 serum proteins displaying significant differential expression between the STS and LTS groups...
May 27, 2024: Molecular Oncology
Roos F Bleckman, Charlotte M S C Haag, Naomi Rifaela, Gerrieke Beukema, Ron H J Mathijssen, Neeltje Steeghs, Hans Gelderblom, Ingrid M E Desar, Arjen Cleven, Arja Ter Elst, Ed Schuuring, Anna K L Reyners
Patients with gastro-intestinal stromal tumors (GISTs) undergoing tyrosine kinase inhibitor therapy are monitored with regular computed tomography (CT) scans, exposing patients to cumulative radiation. This exploratory study aimed to evaluate circulating tumor DNA (ctDNA) testing to monitor treatment response and compare changes in ctDNA levels with RECIST 1.1 and total tumor volume measurements. Between 2014 and 2021, six patients with KIT proto-oncogene, receptor tyrosine kinase (KIT) exon-11-mutated GIST from whom long-term plasma samples were collected prospectively were included in the study...
May 24, 2024: Molecular Oncology
Emilia Alors-Pérez, Ricardo Blázquez-Encinas, María Trinidad Moreno-Montilla, Víctor García-Vioque, Juan Manuel Jiménez-Vacas, Andrea Mafficini, Iranzu González-Borja, Claudio Luchini, Juan M Sánchez-Hidalgo, Marina E Sánchez-Frías, Sergio Pedraza-Arevalo, Antonio Romero-Ruiz, Rita T Lawlor, Antonio Viúdez, Manuel D Gahete, Aldo Scarpa, Álvaro Arjona-Sánchez, Raúl M Luque, Alejandro Ibáñez-Costa, Justo P Castaño
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer, characterized by late diagnosis and poor treatment response. Surgery is the only curative approach, only available to early-diagnosed patients. Current therapies have limited effects, cause severe toxicities, and minimally improve overall survival. Understanding of splicing machinery alterations in PDAC remains incomplete. Here, we comprehensively examined 59 splicing machinery components, uncovering dysregulation in pre-mRNA processing factor 8 (PRPF8) and RNA-binding motif protein X-linked (RBMX)...
May 24, 2024: Molecular Oncology
Manouk K Bos, Jaco Kraan, Martijn P A Starmans, Jean C A Helmijr, Noortje Verschoor, Maja J A De Jonge, Arjen Joosse, Astrid A M van der Veldt, Peter A W Te Boekhorst, John W M Martens, Stefan Sleijfer, Saskia M Wilting
Advances in therapeutic approaches for melanoma urge the need for biomarkers that can identify patients at risk for recurrence and to guide treatment. The potential use of liquid biopsies in identifying biomarkers is increasingly being recognized. Here, we present a head-to-head comparison of several techniques to analyze circulating tumor cells (CTCs) and cell-free DNA (cfDNA) in 20 patients with metastatic melanoma. In this study, we investigated whether diagnostic leukapheresis (DLA) combined with multimarker flow cytometry (FCM) increased the detection of CTCs in blood compared to the CellSearch platform...
May 24, 2024: Molecular Oncology
Jing Liang, Aishwarya Gondane, Harri M Itkonen
Inactivation of cyclin-dependent kinase 12 (CDK12) characterizes an aggressive sub-group of castration-resistant prostate cancer (CRPC). Hyper-activation of MYC transcription factor is sufficient to confer the CRPC phenotype. Here, we show that loss of CDK12 promotes MYC activity, which renders the cells dependent on the otherwise non-essential splicing regulatory kinase SRSF protein kinase 1 (SRPK1). High MYC expression is associated with increased levels of SRPK1 in patient samples, and overexpression of MYC sensitizes prostate cancer cells to SRPK1 inhibition using pharmacological and genetic strategies...
May 22, 2024: Molecular Oncology
Doryan Masmoudi, Jérome Vialaret, Christophe Hirtz, Catherine Alix-Panabières
Circulating tumor cells (CTCs) are cancer cells that detach from the original site and reach the bloodstream. The most aggressive CTCs survive various immune system attacks and initiate metastasis formation. Importantly, CTCs are not specifically targeted by the current immunotherapies due to the limited knowledge on specific targets. Proteomic profiling can be a powerful tool for understanding some of the immune evasion mechanisms used by cancer cells and particularly CTCs. These mechanisms are generally linked to the expression of specific surface proteins/peptides (i...
May 22, 2024: Molecular Oncology
Hung-Rong Yen, Wen-Chieh Liao, Chia-Hua Chen, Ying-Ai Su, Ying-Wei Huang, Chi Hsiao, Yu-Lun Chou, Yin-Hung Chu, Pin-Keng Shih, Chiung-Hui Liu
Accumulation of abnormal chondroitin sulfate (CS) chains in breast cancer tissue is correlated with poor prognosis. However, the biological functions of these CS chains in cancer progression remain largely unknown, impeding the development of targeted treatment focused on CS. Previous studies identified chondroitin polymerizing factor (CHPF; also known as chondroitin sulfate synthase 2) is the critical enzyme regulating CS accumulation in breast cancer tissue. We then assessed the association between CHPF-associated proteoglycans (PGs) and signaling pathways in breast cancer datasets...
May 21, 2024: Molecular Oncology
Terezia Kurucova, Kamila Reblova, Pavlina Janovska, Jakub Pawel Porc, Veronika Navrkalova, Sarka Pavlova, Jitka Malcikova, Karla Plevova, Boris Tichy, Michael Doubek, Vitezslav Bryja, Jana Kotaskova, Sarka Pospisilova
Early identification of resistant cancer cells is currently a major challenge, as their expansion leads to refractoriness. To capture the dynamics of these cells, we made a comprehensive analysis of disease progression and treatment response in a chronic lymphocytic leukemia (CLL) patient using a combination of single-cell and bulk genomic methods. At diagnosis, the patient presented with unfavorable genetic markers, including notch receptor 1 (NOTCH1) mutation and loss(11q). The initial and subsequent treatment lines did not lead to a durable response and the patient developed refractory disease...
May 21, 2024: Molecular Oncology
Lilly Anne Torland, Xiaoran Lai, Surendra Kumar, Margit H Riis, Jürgen Geisler, Torben Lüders, Xavier Tekpli, Vessela Kristensen, Kristine Sahlberg, Andliena Tahiri
Benign breast tumors are a nonthreatening condition defined as abnormal cell growth within the breast without the ability to invade nearby tissue. However, benign lesions hold valuable biological information that can lead us toward better understanding of tumor biology. In this study, we have used two pathway analysis algorithms, Pathifier and gene set variation analysis (GSVA), to identify biological differences between normal breast tissue, benign tumors and malignant tumors in our clinical dataset. Our results revealed that one-third of all pathways that were significantly different between benign and malignant tumors were immune-related pathways, and 227 of them were validated by both methods and in the METABRIC dataset...
May 16, 2024: Molecular Oncology
Asli Küçükosmanoglu, Carolien L van der Borden, Lisanne E A de Boer, Roel Verhaak, David Noske, Tom Wurdinger, Teodora Radonic, Bart A Westerman
Genetic heterogeneity in tumors can show a remarkable selectivity when two or more independent genetic events occur in the same gene. This phenomenon, called composite mutation, points toward a selective pressure, which frequently causes therapy resistance to mutation-specific drugs. Since composite mutations have been described to occur in sub-clonal populations, they are not always captured through biopsy sampling. Here, we provide a proof of concept to predict composite mutations to anticipate which patients might be at risk for sub-clonally driven therapy resistance...
May 16, 2024: Molecular Oncology
Laura Andersen, Ditte S Christensen, Asbjørn Kjær, Michael Knudsen, Andreas K Andersen, Maria B Laursen, Johanne Ahrenfeldt, Britt E Laursen, Nicolai J Birkbak
Cancer of unknown primary (CUP) tumors are biologically very heterogeneous, which complicates stratification of patients for treatment. Consequently, these patients face limited treatment options and a poor prognosis. With this study, we aim to expand on the current knowledge of CUP biology by analyzing two cohorts: a well-characterized cohort of 44 CUP patients, and 213 metastatic patients with known primary. These cohorts were treated at the same institution and characterized by identical molecular assessments...
May 15, 2024: Molecular Oncology
Yi-Cheng Pan, Pei-Yi Chu, Ching-Chan Lin, Ching-Yun Hsieh, Wei-Yu Hsu, Lie-Fen Shyur, Juan-Cheng Yang, Wei-Chao Chang, Yang-Chang Wu
Bladder cancer poses a significant challenge to chemotherapy due to its resistance to cisplatin, especially at advanced stages. Understanding the mechanisms behind cisplatin resistance is crucial for improving cancer therapy. The enzyme glutathione S-transferase omega class 1 (GSTO1) is known to be involved in cisplatin resistance in colon cancer. This study focused on its role in cisplatin resistance in bladder cancer. Our analysis of protein expression in bladder cancer cells stimulated by secretions from tumor-associated macrophages (TAMs) showed a significant increase in GSTO1...
May 15, 2024: Molecular Oncology
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.